ME02450B - POBOLJŠANO LIJEČENJE MULTlPLOG MIJELOMA - Google Patents

POBOLJŠANO LIJEČENJE MULTlPLOG MIJELOMA

Info

Publication number
ME02450B
ME02450B MEP-2016-115A MEP11516A ME02450B ME 02450 B ME02450 B ME 02450B ME P11516 A MEP11516 A ME P11516A ME 02450 B ME02450 B ME 02450B
Authority
ME
Montenegro
Prior art keywords
improved antitumoral
antitumoral treatments
treatments
improved
antitumoral
Prior art date
Application number
MEP-2016-115A
Other languages
English (en)
French (fr)
Inventor
Glynn Thomas Faircloth
Marin Pablo Manuel Aviles
Doreen Lepage
Miguel Izquierdo Jesus San
Atanasio Pandiella
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of ME02450B publication Critical patent/ME02450B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
MEP-2016-115A 2006-02-28 2007-02-28 POBOLJŠANO LIJEČENJE MULTlPLOG MIJELOMA ME02450B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81360606P 2006-02-28 2006-02-28
PCT/US2007/062936 WO2007101235A2 (en) 2006-02-28 2007-02-28 Improved antitumoral treatments
EP07757603.1A EP2029155B1 (en) 2006-02-28 2007-02-28 Improved treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
ME02450B true ME02450B (me) 2016-09-20

Family

ID=38459806

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-115A ME02450B (me) 2006-02-28 2007-02-28 POBOLJŠANO LIJEČENJE MULTlPLOG MIJELOMA

Country Status (24)

Country Link
US (1) US8258098B2 (me)
EP (1) EP2029155B1 (me)
JP (2) JP5393159B2 (me)
KR (2) KR101512503B1 (me)
CN (1) CN101389347B (me)
AU (1) AU2007220050B2 (me)
CA (1) CA2643238C (me)
CY (1) CY1117722T1 (me)
DK (1) DK2029155T3 (me)
ES (1) ES2575518T3 (me)
HK (1) HK1127294A1 (me)
HR (1) HRP20160646T1 (me)
HU (1) HUE028055T2 (me)
IL (1) IL193094A (me)
ME (1) ME02450B (me)
MX (1) MX2008010999A (me)
NO (1) NO342012B1 (me)
NZ (1) NZ571043A (me)
PL (1) PL2029155T3 (me)
PT (1) PT2029155E (me)
RS (1) RS54928B1 (me)
RU (1) RU2481853C2 (me)
SI (1) SI2029155T1 (me)
WO (1) WO2007101235A2 (me)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE363910T1 (de) * 1999-11-15 2007-06-15 Pharma Mar Sa Behandlung von krebserkrankungen durch aplidin
ES2575518T3 (es) 2006-02-28 2016-06-29 Pharma Mar S.A. Tratamiento mejorado de mieloma múltiple
WO2008135793A1 (en) * 2007-05-04 2008-11-13 Pharma Mar S.A. Combination of aplidine and carboplatin in anticancer treatments
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
RU2010140890A (ru) * 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) Улучшенные способы противоопухолевого лечения
CN101965191A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗癌治疗
MX337566B (es) * 2010-01-05 2016-03-10 Celgene Corp Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
BR122017028570B1 (pt) * 2010-11-12 2022-03-03 Pharma Mar, S.A Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit
WO2012075211A2 (en) * 2010-12-01 2012-06-07 Niiki Pharma Inc. Combination therapy with a gallium complex
LT2776032T (lt) * 2011-11-09 2018-12-10 Bristol-Myers Squibb Company Hematologinių piktybinių navikų gydymas anti-cxcr4 antikūnu
KR101369936B1 (ko) * 2011-12-28 2014-03-06 연세대학교 산학협력단 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물
RU2547999C1 (ru) * 2013-10-28 2015-04-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения аденогенного местно-распространенного рака нижнеампулярного отдела прямой кишки
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US20220026432A1 (en) * 2018-12-14 2022-01-27 Konica Minolta, Inc. Method for forecasting arrival of drug inside diseased tissue
CN113018415B (zh) * 2021-03-17 2022-07-01 遵义医科大学 一种药物组合及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
ATE74761T1 (de) * 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
JP2001503746A (ja) 1996-10-24 2001-03-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニン類似体の半合成法
DE69723728T2 (de) 1996-10-24 2004-06-03 The Board Of Trustees For The University Of Illinois, Urbana Totalsynthese des amino hip analogen von didemnin a
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
DE69840497D1 (de) * 1997-05-07 2009-03-12 William J Crumb Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
RU2266734C2 (ru) * 1999-05-13 2005-12-27 Фарма Мар, С.А. Композиции и применение ет743 для лечения злокачественных опухолей
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
ATE363910T1 (de) * 1999-11-15 2007-06-15 Pharma Mar Sa Behandlung von krebserkrankungen durch aplidin
WO2001076616A1 (en) * 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU9402401A (en) * 2000-10-12 2002-04-22 Pharma Mar Sa Treatment of cancers
BR0114604A (pt) * 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
CA2435418A1 (en) 2001-01-24 2002-08-01 Mestex Ag Use of neurotoxic substances in producing a medicament for treating joint pains
PT1435991E (pt) 2001-10-19 2009-01-16 Pharma Mar Sa Utilização de aplidina para o tratamento de cancro pancreático
AU2004218883B2 (en) * 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
KR20060002778A (ko) * 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
WO2004084812A2 (en) 2003-03-21 2004-10-07 Joullie Madeleine M Tamandarin analogs and fragments thereof and methods of making and using
JP2007516693A (ja) * 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
ES2575518T3 (es) 2006-02-28 2016-06-29 Pharma Mar S.A. Tratamiento mejorado de mieloma múltiple
DE102006061344A1 (de) * 2006-12-22 2008-06-26 Robert Bosch Gmbh Kupplungshydraulikkreis
WO2008080956A1 (en) 2006-12-29 2008-07-10 Pharma Mar, S.A. Prognostic molecular markers for the cancer therapy with aplidine
WO2008135793A1 (en) 2007-05-04 2008-11-13 Pharma Mar S.A. Combination of aplidine and carboplatin in anticancer treatments
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
WO2010029158A1 (en) 2008-09-12 2010-03-18 Pharma Mar, S.A. Aplidine in the treatment of chronic myeloproliferative disorders

Also Published As

Publication number Publication date
US20090246168A1 (en) 2009-10-01
KR20080105123A (ko) 2008-12-03
NO20084047L (no) 2008-11-25
HK1127294A1 (zh) 2009-09-25
CN101389347A (zh) 2009-03-18
KR101512503B1 (ko) 2015-04-15
RS54928B1 (sr) 2016-10-31
JP5393159B2 (ja) 2014-01-22
US8258098B2 (en) 2012-09-04
RU2008138560A (ru) 2010-04-10
CA2643238A1 (en) 2007-09-07
EP2029155A2 (en) 2009-03-04
RU2481853C2 (ru) 2013-05-20
CN101389347B (zh) 2013-03-27
JP2009528379A (ja) 2009-08-06
PT2029155E (pt) 2016-06-17
JP2013199500A (ja) 2013-10-03
EP2029155B1 (en) 2016-04-13
KR20140101014A (ko) 2014-08-18
HUE028055T2 (en) 2016-11-28
DK2029155T3 (en) 2016-08-01
PL2029155T3 (pl) 2016-09-30
ES2575518T3 (es) 2016-06-29
SI2029155T1 (sl) 2016-06-30
CA2643238C (en) 2016-05-03
WO2007101235A3 (en) 2008-04-03
WO2007101235A2 (en) 2007-09-07
CY1117722T1 (el) 2017-05-17
NO342012B1 (no) 2018-03-12
IL193094A0 (en) 2011-08-01
MX2008010999A (es) 2008-09-08
HRP20160646T1 (hr) 2016-08-12
AU2007220050A1 (en) 2007-09-07
EP2029155A4 (en) 2009-10-14
AU2007220050B2 (en) 2013-08-29
IL193094A (en) 2015-06-30
NZ571043A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
IL193094A0 (en) Improved antitumoral treatments
IL196559A0 (en) Combination therapy
GB0624874D0 (en) Treatment
EP2073891A4 (en) PACEMAKER
GB0600692D0 (en) Well treatment
IL196556A0 (en) Combination therapy
IL208000A0 (en) Improved antitumoral treatments
EP2230910A4 (en) PRE-SURGICAL TREATMENT
EP2054061A4 (en) COMBINATION THERAPY
ZA200810315B (en) Antitumoral dihydropyran-2-one compounds
GB0711342D0 (en) Well treatment
EP2089122A4 (en) GAMING APPARATUS
GB0621527D0 (en) Acne treatment
IL205096A0 (en) Improved antitumoral treatments
ZA200902203B (en) Combination therapy
GB0607952D0 (en) Novel treatment
GB0716784D0 (en) Well treatment
GB0626038D0 (en) Common-hand all games
GB0721535D0 (en) Surface modifying treatments
GB0604460D0 (en) Treatment
GB0605781D0 (en) Treatment
GB0610431D0 (en) Treatment
GB0605081D0 (en) Antitumoral compounds
GB0622870D0 (en) Antitumoral compounds
GB0623952D0 (en) Antitumoral compounds